Daily non-political popular news in brief.

Long-term ulcerative colitis study shows Remicade responders maintained improvement

Findings presented today at Digestive Disease Week 2007, from long-term extensions of the ACT trials show that subjects with moderately to severely active ulcerative colitis who had responded to REMICADE in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

Read more »

Keywords: long-term, ulcerative, colitis, study, shows, remicade, responders, maintained, improvement, long, term, coliti, show, responder

« Previous | Next »

Similar news on "Long-term ulcerative colitis study shows Remicade responders maintained improvement":

1. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
   10-23-2006 · EurekAlert!
   Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
   Similar news · Read more »
   
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
   10-15-2007 · EurekAlert!
   REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis. According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials, there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo.
   Similar news · Read more »
   
3. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
   10-15-2007 · EurekAlert!
   Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
   Similar news · Read more »
   
4. New long-term data analyses for Bifeprunox show favorable effects vs. placebo
   05-22-2007 · EurekAlert!
   Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth, and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.
   Similar news · Read more »
   
5. Study shows variety of approaches help children overcome auditory processing and language problems
   01-30-2008 · EurekAlert!
   A study comparing four intervention strategies in children who have unusual difficulty understanding and using language found that all four methods resulted in significant, long-term improvements in the children's language abilities. The aim of the study was to assess whether children who used commercially available language software program Fast ForWord-Language had greater improvement in language skills than children using other methods.
   Similar news · Read more »
   
6. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
7. Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW
   05-22-2007 · EurekAlert!
   A long-term phase III, open-label 12-14 month extension study presented at the British Society of Gastroenterology meeting in Glasgow, Scotland, in March 2007 showed Shire plc's LIALDA is well-tolerated in mild-to-moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week.
   Similar news · Read more »
   
8. Study shows that targeted antibiotics lead to prolonged improvement in IBS symptoms
   10-16-2006 · EurekAlert!
   Researchers at Cedars-Sinai Medical Center have found that a nonabsorbable antibiotic -- one that stays in the gut -- can be an effective long-term treatment for irritable bowel syndrome (IBS), a disease affecting more than 20 percent of Americans.
   Similar news · Read more »
   
9. Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
   10-23-2006 · EurekAlert!
   While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Tthe study's authors say potential improvement in cancer-free survival beyond five years with the added therapy may be less than two percent for most patients.
   Similar news · Read more »
   
10. Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation
    06-15-2007 · EurekAlert!
    Data presented today at the European League Against Rheumatism Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis who received Remicade over two years experienced significant improvement in spinal mobility. In addition, Remicade-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging.
    Similar news · Read more »